An Adaptive Dose-Ranging, Multi-Center, Single-Blind, Double-Dummy, Active-Controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine.

Trial Profile

An Adaptive Dose-Ranging, Multi-Center, Single-Blind, Double-Dummy, Active-Controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs Canakinumab (Primary) ; Triamcinolone
  • Indications Gout; Gouty arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jun 2012 Planned patient number of extension trial (EudraCT2009-012316-40) changed from 300 to 320.
    • 23 Jun 2012 Planned patient number of extension trial (EudraCT2009-012316-40) changed from 300 to 320.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top